Decisions / 5955
final resolution2023-04-06active

Arzneimittel-Richtlinie/Anlage XII: Faricimab (Diabetisches Makulaödem)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene mit Visusbeeinträchtigung aufgrund eines diabetischen Makulaödems (DMÖ)

Added benefit not proven

Comparator
− Ranibizumab oder Aflibercept

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2023-04-06
Effective
06.04.2023
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package